Logo image of ETON

ETON PHARMACEUTICALS INC (ETON) Stock Fundamental Analysis

NASDAQ:ETON - Nasdaq - US29772L1089 - Common Stock - Currency: USD

19.6  +0.03 (+0.15%)

After market: 19.6 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ETON. ETON was compared to 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ETON have multiple concerns. ETON is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

ETON had negative earnings in the past year.
ETON had a positive operating cash flow in the past year.
In the past 5 years ETON always reported negative net income.
In multiple years ETON reported negative operating cash flow during the last 5 years.
ETON Yearly Net Income VS EBIT VS OCF VS FCFETON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

With a decent Return On Assets value of -5.02%, ETON is doing good in the industry, outperforming 74.75% of the companies in the same industry.
ETON has a Return On Equity of -15.65%. This is in the better half of the industry: ETON outperforms 74.24% of its industry peers.
Industry RankSector Rank
ROA -5.02%
ROE -15.65%
ROIC N/A
ROA(3y)-14.67%
ROA(5y)-31.48%
ROE(3y)-30.22%
ROE(5y)-56.08%
ROIC(3y)N/A
ROIC(5y)N/A
ETON Yearly ROA, ROE, ROICETON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

With a decent Gross Margin value of 60.01%, ETON is doing good in the industry, outperforming 67.68% of the companies in the same industry.
ETON's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for ETON so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.67%
GM growth 5Y2.47%
ETON Yearly Profit, Operating, Gross MarginsETON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

3

2. Health

2.1 Basic Checks

ETON does not have a ROIC to compare to the WACC, probably because it is not profitable.
ETON has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ETON has been increased compared to 5 years ago.
Compared to 1 year ago, ETON has a worse debt to assets ratio.
ETON Yearly Shares OutstandingETON Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ETON Yearly Total Debt VS Total AssetsETON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 4.86 indicates that ETON is not in any danger for bankruptcy at the moment.
The Altman-Z score of ETON (4.86) is better than 80.81% of its industry peers.
ETON has a Debt/Equity ratio of 1.22. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.22, ETON is doing worse than 72.22% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.22
Debt/FCF N/A
Altman-Z 4.86
ROIC/WACCN/A
WACC9.77%
ETON Yearly LT Debt VS Equity VS FCFETON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

ETON has a Current Ratio of 2.06. This indicates that ETON is financially healthy and has no problem in meeting its short term obligations.
ETON has a Current ratio (2.06) which is comparable to the rest of the industry.
ETON has a Quick Ratio of 1.29. This is a normal value and indicates that ETON is financially healthy and should not expect problems in meeting its short term obligations.
ETON has a Quick ratio of 1.29. This is in the lower half of the industry: ETON underperforms 68.18% of its industry peers.
Industry RankSector Rank
Current Ratio 2.06
Quick Ratio 1.29
ETON Yearly Current Assets VS Current LiabilitesETON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

7

3. Growth

3.1 Past

ETON shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -500.00%.
ETON shows a strong growth in Revenue. In the last year, the Revenue has grown by 23.29%.
ETON shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 109.79% yearly.
EPS 1Y (TTM)-500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
Revenue 1Y (TTM)23.29%
Revenue growth 3Y21.35%
Revenue growth 5Y109.79%
Sales Q2Q%116.95%

3.2 Future

The Earnings Per Share is expected to grow by 85.99% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 43.04% on average over the next years. This is a very strong growth
EPS Next Y474%
EPS Next 2Y242.97%
EPS Next 3Y149.41%
EPS Next 5Y85.99%
Revenue Next Year100.04%
Revenue Next 2Y74.16%
Revenue Next 3Y59.2%
Revenue Next 5Y43.04%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ETON Yearly Revenue VS EstimatesETON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ETON Yearly EPS VS EstimatesETON Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ETON. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 14.34, the valuation of ETON can be described as correct.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ETON indicates a rather cheap valuation: ETON is cheaper than 81.31% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of ETON to the average of the S&P500 Index (22.43), we can say ETON is valued slightly cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 14.34
ETON Price Earnings VS Forward Price EarningsETON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200 -300 -400

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ETON Per share dataETON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

ETON's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ETON's earnings are expected to grow with 149.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y242.97%
EPS Next 3Y149.41%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ETON!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ETON PHARMACEUTICALS INC

NASDAQ:ETON (5/20/2025, 8:00:01 PM)

After market: 19.6 0 (0%)

19.6

+0.03 (+0.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)N/A N/A
Inst Owners49.94%
Inst Owner Change7.58%
Ins Owners5.61%
Ins Owner Change2.48%
Market Cap525.67M
Analysts82.22
Price Target28.22 (43.98%)
Short Float %2.77%
Short Ratio2.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-47.35%
Min EPS beat(2)-488.82%
Max EPS beat(2)394.12%
EPS beat(4)2
Avg EPS beat(4)-32.03%
Min EPS beat(4)-488.82%
Max EPS beat(4)394.12%
EPS beat(8)5
Avg EPS beat(8)15.63%
EPS beat(12)7
Avg EPS beat(12)-1.22%
EPS beat(16)8
Avg EPS beat(16)-8.77%
Revenue beat(2)2
Avg Revenue beat(2)6.42%
Min Revenue beat(2)4.4%
Max Revenue beat(2)8.43%
Revenue beat(4)3
Avg Revenue beat(4)2.89%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)8.43%
Revenue beat(8)6
Avg Revenue beat(8)13.7%
Revenue beat(12)7
Avg Revenue beat(12)2.3%
Revenue beat(16)7
Avg Revenue beat(16)-7.74%
PT rev (1m)0%
PT rev (3m)7.79%
EPS NQ rev (1m)166.65%
EPS NQ rev (3m)99.96%
EPS NY rev (1m)28.33%
EPS NY rev (3m)-1.28%
Revenue NQ rev (1m)5.58%
Revenue NQ rev (3m)12.11%
Revenue NY rev (1m)3.08%
Revenue NY rev (3m)-5.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 14.34
P/S 13.47
P/FCF N/A
P/OCF 542.49
P/B 21.52
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)1.37
Fwd EY6.97%
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)0.04
OCFY0.18%
SpS1.45
BVpS0.91
TBVpS-0.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.02%
ROE -15.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.01%
FCFM N/A
ROA(3y)-14.67%
ROA(5y)-31.48%
ROE(3y)-30.22%
ROE(5y)-56.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.67%
GM growth 5Y2.47%
F-Score3
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 1.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 873.82%
Cap/Sales 25.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.06
Quick Ratio 1.29
Altman-Z 4.86
F-Score3
WACC9.77%
ROIC/WACCN/A
Cap/Depr(3y)372.49%
Cap/Depr(5y)366.77%
Cap/Sales(3y)13.75%
Cap/Sales(5y)36.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
EPS Next Y474%
EPS Next 2Y242.97%
EPS Next 3Y149.41%
EPS Next 5Y85.99%
Revenue 1Y (TTM)23.29%
Revenue growth 3Y21.35%
Revenue growth 5Y109.79%
Sales Q2Q%116.95%
Revenue Next Year100.04%
Revenue Next 2Y74.16%
Revenue Next 3Y59.2%
Revenue Next 5Y43.04%
EBIT growth 1Y-82.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year697.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-249.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-85.78%
OCF growth 3YN/A
OCF growth 5YN/A